Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Celltrion files for Approval of Remicade Biosimilar in US

publication date: Aug 12, 2014
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Celltrion, a Korean biotech, filed with the FDA for approval of Remsima®, a biosimilar to Janssen’s Remicade, which is indicated for autoimmune diseases. Remsima is the first monoclonal antibody to seek approval in the US under the 351(k) rules for biosimilars. In 2009, Celltrion and Hospira agreed to become co-exclusive distributors of Remsima as part of a package of eight biosimilars (now expanded to eleven) under development at Celltrion. More details....

Stock Symbols: (KOSDAQ: 068270) (NYSE: HSP)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at this event:
 
 
Hope to see you there!
 
ChinaBio® Events
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors